Welcome to our dedicated page for Veradigm news (Ticker: MDRX), a resource for investors and traders seeking the latest updates and insights on Veradigm stock.
Veradigm Inc. reports developments tied to its healthcare data and technology business, including clinical and revenue cycle solutions for independent medical practices and data-driven offerings across provider, payer and biopharma markets. Company updates frequently reference the Veradigm Network, EHR-based analytics, real-world evidence, value-based care workflows, payer insights, coding services and revenue cycle management.
Recurring news also covers financial and business updates, financing activity, customer selections, product and content initiatives, leadership changes, stockholder rights-plan actions and the company’s reporting-status matters. These updates frame Veradigm as a healthcare technology issuer whose common stock trades under MDRX on the OTC market.
Allscripts Healthcare Solutions (NASDAQ: MDRX) will report its Q3 2020 financial results after market close on October 29, 2020. A conference call and webcast detailing the results will follow at 4:30 PM ET. Investors can access the announcement on the company’s investor relations website. The earnings report marks a significant event for stakeholders as it provides insights into the company's financial health and operational performance during the quarter.
Allscripts (NASDAQ: MDRX) has completed the sale of its subsidiary, EPSi, to Strata Decision Technology for $365 million as of October 15. EPSi specializes in providing financial decision support tools for healthcare institutions. This strategic divestiture aligns with Allscripts' objectives to optimize its healthcare information technology offerings and streamline operations.
Allscripts (NASDAQ:MDRX) has announced the sale of its CarePort Health business to WellSky Corp. for $1.35 billion. This deal values CarePort at over 13 times its revenue and 21 times its non-GAAP Adjusted EBITDA. CarePort constitutes approximately 6% of Allscripts' consolidated revenues. The transaction is set to close by year-end, pending regulatory approvals. Proceeds from the sale will be utilized to enhance Allscripts' solutions, reduce debt, and support share repurchases. Management believes this move unlocks significant value for shareholders and allows a sharper focus on core operations.
Allscripts (NASDAQ: MDRX) continues to enhance healthcare interoperability through its dbMotion™ solution, which supports over 14M unique patient transactions monthly. The platform enables clinicians to access real-time patient data across various EHR systems, improving care outcomes globally. Recent achievements include sharing over 1B patient demographics and 650M observation results. Recognized by Frost & Sullivan as a leader in healthcare data interoperability, Allscripts aims to connect healthcare data to improve patient care and lower costs.